Study Enrollment

Your details will not be published or shared.

Clinical Trial

MK3475-826 A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Chemotherapy Plus Placebo for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826)

The purpose of this study is to test the safety of the research study drug, pembrolizumab (MK-3475) in combination with chemotherapy, compared to chemotherapy plus placebo (a look-alike drug with no active inredients) in women with persistent, recurrent, or metastatic cervical cancer. Also, to test if adding pembrolizumab (MK-3475) to standard chemotherapy improves survival in women with persistent, recurrent, or metastic cervical cancer.

Eligibility Criteria

  • -Participants must be female, at least 18 years of age or older - Participants must have persistent, recurrent, or metastatic squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix which has not been treated with systemic chemotherapy and is not responsive to treatments such as surgery and/or radiation - Women of child bearing potential who have had a positive urine pregnancy test within 72 hours prior to randomization are excluded from participation

Contact Information

    Renee Townsend, RN

    (706) 721-3473